BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019
LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for…